The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.
 
Filipa Lynce
Research Funding - Bristol-Myers Squibb; Pfizer
 
Ana Barac
Research Funding - Genentech/Roche (Inst)
 
Xue Geng
No Relationships to Disclose
 
Chau T. Dang
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Genentech
 
Anthony Francis Yu
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Glenmark; Takeda
 
Karen L. Smith
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I)
Research Funding - Galena Biopharma (Inst); Pfizer (Inst)
 
Christopher Gallagher
Honoraria - Genomic Health
 
Paula Raffin Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Consulting or Advisory Role - HERON; Immunonet BioSciences; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer
Research Funding - Advanced Cancer Therapeutics (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - IMMUNOLOGICAL COMPOSITIONS AS CANCER BIOMARKERS AND/OR THERAPEUTICS; U.S. Patent and Trademark Office No. US 20120201820. Invention title: Immunological Compositions as Cancer Therapeutics.
 
Raquel Nunes
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Caris Life Sciences
 
Pia Maarit Herbolsheimer
Employment - AstraZeneca
 
Robert D. Warren
No Relationships to Disclose
 
M. Barbara Srichai
No Relationships to Disclose
 
Mark Hofmeyer
No Relationships to Disclose
 
Andrecia Cunningham
No Relationships to Disclose
 
Patricia Timothee
No Relationships to Disclose
 
Federico M Asch
Research Funding - LivaNova (Inst)
 
Ayesha N Shajahan-Haq
Research Funding - Intezyne Technologies (Inst)
Patents, Royalties, Other Intellectual Property - Georgetown Univ. (Inst)
 
Ming Tony Tan
Honoraria - AstraZeneca; Incyte; Otsuka; Sanofi Pasteur
Consulting or Advisory Role - American Gene Technologies
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Otsuka
 
Claudine Isaacs
Honoraria - AstraZeneca; Celgene; Genentech/Roche; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Medivation; NanoString Technologies; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Celgene; Genentech; Pfizer
Research Funding - Genentech (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Caris Life Sciences
 
Sandra M. Swain
Honoraria - Novartis; Roche
Consulting or Advisory Role - Genentech/Roche; Inivata; Lilly; Pieris Pharmaceuticals
Research Funding - Genentech (Inst); Lilly (Inst); Merrimack; Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Caris Centers of Excellence; Genentech/Roche; Inivata
Other Relationship - AstraZeneca